Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The Netherlands Journal of Medicine|August 31, 2016
Willingness to accept chemotherapy and attitudes towards costs of cancer treatment; A multisite survey study in the NetherlandsE F M M van Dijk, M Coşkuntürk, A T Zuur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2011
A new, simple and objective prognostic score for phase I cancer patientsL M Füssenich, I M E Desar, M E W J Peters, et al.
British Journal of Cancer|May 20, 2004
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulationR Boonstra, H Timmer-Bosscha, J van Echten-Arends, et al.
Lung Cancer (Amsterdam, Netherlands)|November 17, 2007
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancerJ N H Timmer-Bonte, C J A Punt, H F M vd Heijden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999
Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositisA N Wymenga, W T van der Graaf, L S Hofstra, et al.
Blood|May 29, 2000
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activityD M van Der Kolk, E Vellenga, A Y van Der Veen, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targetsH H Nienhuis, S B M Gaykema, H Timmer-Bosscha, et al.
Acta Oncologica (Stockholm, Sweden)|November 26, 2013
Adherence and patients' experiences with the use of oral anticancer agentsLonneke Timmers, Christel C L M Boons, Femke Kropff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2010
The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumoursBernadette G Dijkman, Olga C J Schuurbiers, Dennis Vriens, et al.
European Journal of Radiology|September 25, 2010
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patientsIngrid M E Desar, Carla M L van Herpen, Jack J A van Asten, et al.
Pageof 8